Intermediate-dose HAD Regimen for CEBPA Double-mutated AML

Prior treatment

• Patients who have previously received induction chemotherapy, regardless of efficacy.

Other illness

• Simultaneously suffering from malignant tumors of other organs and requiring treatment).
• Serious infectious diseases (uncured tuberculosis, pulmonary aspergillosis).

Lab values

• Active heart disease, defined as one or more of the following:1) Have a history of uncontrolled or symptomatic angina pectoris;2) Myocardial infarction less than 6 months prior to enrollment in the study;3) A history of arrhythmia requiring medication treatment or severe clinical symptoms;4) Uncontrolled or symptomatic congestive heart failure (\> NYHA grade 2);5) The ejection fraction is below the lower limit of the normal range.

Other

• Pregnant or lactating women. Male or female patients participating in the trial must take contraceptive measures during the trial treatment period.
• Those who were not considered suitable for inclusion by the researchers.

• AML diagnosed according to WHO-2022 classification with recurrent CEBPA mutations and containing mutation in the bZIP domain.
• Older than 14 years old and younger than 55 years old
• Male or female.
• The Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of AML patients were 0-2 points.
• Meet the following laboratory tests (performed within 7 days prior to treatment) 1) Total bilirubin ≤ 1.5 times of the upper limit of normal value (same age); 2) AST and ALT≤ 2.5 times of the upper limit of normal value (same age); 3) Blood creatinine \< 2 times of the upper limit of normal value (same age); 4) Myocardial enzymes \< 2 times of the upper limit of normal value (same age); 5) Echocardiography (ECHO) was performed to determine the ejection fraction of the heart within the normal range.